PatentJun 4, 2026, 10:01 AM
Nexalin Secures US Patent for Deep-Brain Neurostimulation Through 2042
AI Summary
The United States Patent and Trademark Office issued U.S. Patent No. 12,629,519 to Nexalin Technology, Inc. This patent, titled "Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia," provides intellectual property protection for Nexalin's core dynamic frequency stimulation method through 2042. This strengthens the company's long-term competitive position in non-invasive frequency-based deep-brain neurostimulation and supports its HALO Clarity and NeuroCare strategies for large, underserved markets.
Key Highlights
- U.S. Patent No. 12,629,519 issued to Nexalin Technology.
- Patent provides U.S. intellectual property protection through 2042.
- Covers transcranial alternating current dynamic frequency stimulation methods.
- Methods are for anxiety, depression, and insomnia.
- Strengthens Nexalin's proprietary position in deep-brain neurostimulation.
- Reinforces leadership in non-invasive, frequency-based neurostimulation.
- Supports HALO Clarity and Nexalin NeuroCare virtual clinic platforms.
Price Impact
More from NXL